Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy.

ABSTRACT: Monoclonal antibodies (mAbs) have become a cornerstone in the therapeutic guidelines of a wide range of solid tumors. The targeted nature of these biotherapeutics has improved treatment outcomes by offering enhanced specificity to reduce severe side effects experienced with conventional chemotherapy. Notwithstanding, poor tumor tissue penetration and the heterogeneous distribution achieved therein are prominent drawbacks that hamper the clinical efficacy of therapeutic antibodies. Failure to deliver efficacious doses throughout the tumor can lead to treatment failure and the development of acquired resistance mechanisms. Comprehending the morphological and physiological characteristics of solid tumors and their microenvironment that affect tumor penetration and distribution is a key requir

SUBMITTER: Cruz E 

PROVIDER: S-EPMC6503308 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature